8-K: Integer Holdings Reports Strong 2025, Tightens 2026 Outlook

Integer Holdings Corporation announced robust full-year 2025 financial results with 8% sales growth and 21% adjusted EPS growth, while tightening its 2026 outlook.

Summary

• Full-year 2025 sales increased 8% to $1.854 billion.
• Full-year 2025 adjusted EPS increased 21% to $6.40 per share.
• Full-year 2025 adjusted operating income increased 13% to $321 million.
• Fourth quarter 2025 sales increased 5% to $472 million.
• Fourth quarter 2025 adjusted EPS increased 23% to $1.76 per share.
• The company repurchased 698,356 common shares for $50 million in 2025.
• Total debt increased $195 million to $1.185 billion, with a leverage ratio of 3.0x adjusted EBITDA as of December 31, 2025.
• The 2026 outlook projects sales between $1.826 billion and $1.876 billion (a change of -1% to 1% from prior year), and adjusted EPS between $6.29 and $6.78 (a change of -2% to 6% from prior year).
• The company expects to return to 200 basis points above-market organic sales growth in 2027.
• Integer Holdings intends to commence an Accelerated Share Repurchase (ASR) program of approximately $50 million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, demonstrating strong 2025 performance and a confident, albeit refined, outlook for 2026 and beyond, despite some segment-specific challenges and increased debt.

Positives

• Full-year 2025 sales increased 8% to $1.854 billion compared to full year 2024.
• Full-year 2025 adjusted EPS increased 21% to $6.40 per share compared to full year 2024.
• Full-year 2025 adjusted operating income increased 13% to $321 million compared to full year 2024.
• Fourth quarter 2025 sales increased 5% to $472 million compared to fourth quarter 2024.
• Fourth quarter 2025 adjusted EPS increased 23% to $1.76 per share compared to fourth quarter 2024.
• Fourth quarter 2025 adjusted operating income increased 10% to $83 million compared to fourth quarter 2024.
• Fourth quarter 2025 adjusted EBITDA increased 11% to $106 million compared to fourth quarter 2024.
• Cardio & Vascular sales increased 11% to $284 million in Q4 2025 and 17% to $1.107 billion for the full year 2025, driven by acquisitions and strong demand in Neurovascular.
• Generated $196 million of cash flow from operating activities in 2025.
• The company repurchased 698,356 common shares for $50 million in 2025.
• Integer Holdings expects to return to 200 basis points above-market organic sales growth in 2027.

Negatives

• Fourth quarter 2025 GAAP operating income decreased 2% to $56 million.
• Full-year 2025 GAAP income from continuing operations decreased 15% to $103 million.
• Full-year 2025 GAAP diluted EPS from continuing operations decreased 15% to $2.89 per share.
• Cardiac Rhythm Management & Neuromodulation sales decreased 2% to $167 million in Q4 2025, primarily due to a decline in Neuromodulation from lower demand from select emerging customers.
• Other Markets sales decreased 13% to $21 million in Q4 2025 and 27% to $78 million for the full year 2025, driven by the multi-year exit from Portable Medical.
• Total debt increased $195 million to $1.185 billion, and non-GAAP net total debt increased $236 million to $1.190 billion, primarily to finance acquisitions, convertible notes offering costs, and share repurchases.
• The 2026 outlook for GAAP operating income projects a decrease of 8% to 17%.
• The 2026 outlook for adjusted net income projects a decrease of 4% to an increase of 3%.
• The 2026 outlook for adjusted EPS projects a decrease of 2% to an increase of 6%.

Risks

• Dependence upon a limited number of customers.
• Reductions, delays, or cancellations in demand from any significant customer or group of customers.
• Pricing pressures and contractual pricing restraints from customers.
• Reliance on third-party suppliers for raw materials, key products, and subcomponents.
• The cost of raw materials, products, and subcomponents that are incorporated into products.
• Trade regulations and changes in order forecasts.
• Ability to predict and meet the demand for products.
• Interruptions in manufacturing operations.
• Uncertainty surrounding macroeconomic and geopolitical factors in the U.S. and globally.
• Ability to attract, train, and retain a sufficient number of qualified associates.
• Potential for harm to reputation and competitive advantage caused by quality problems related to products.
• Dependence upon information technology systems and ability to prevent cyber-attacks and other failures.
• Global climate change and the emphasis on Environmental, Social, and Governance matters by various stakeholders.
• Dependence upon the senior management team and key technical personnel.
• Consolidation in the healthcare industry both at a competitor and customer level resulting in increased competition and pricing pressure.
• Intense competition and ability to successfully market current or new products.
• Ability to recover the R&D investments made in the development of new products.
• Customers in-sourcing or dual sourcing production.
• Ability to respond to changes in technology.
• Ability to develop new products and expand into new geographic and product markets.
• Ability to successfully identify, make, and integrate acquisitions.
• Ability to accurately forecast future performance based on operating results that often fluctuate.
• Volatility of stock price and failure to meet publicly announced guidance.
• The ability of the share repurchase program, including the ASR, to enhance shareholder value.
• Shareholder activism.
• Significant amount of outstanding indebtedness and ability to remain in compliance with financial and other covenants.
• Economic and credit market uncertainties that could interrupt access to capital markets, borrowings, or financial transactions.
• Conditional conversion features of Convertible Notes adversely impacting liquidity.
• The conversion of Convertible Notes diluting ownership interests of existing holders of common stock.
• Counterparty risk associated with capped call transactions.
• Financial and market risks related to international sales and operations.
• Complex international tax profile.
• Ability to realize the full value of intangible assets.
• Legal proceedings against the company.
• Regulatory issues resulting from product complaints, recalls, or regulatory audits.
• The potential of becoming subject to product liability or intellectual property claims.
• Ability to protect intellectual property and proprietary rights.
• Ability to comply with customer-driven policies and third-party standards or certification requirements.
• Ability to obtain and/or retain necessary licenses from third parties for new technologies.
• Ability and the cost to comply with environmental regulations.
• Legal and regulatory risks from international operations.
• The fact that the healthcare industry is highly regulated and subject to various regulatory changes.
• Business being indirectly subject to healthcare industry cost containment measures and third-party coverage and reimbursement policies that could result in reduced sales of products.

Future Outlook

The company has tightened its 2026 outlook range, maintaining the midpoint of sales growth and the high end of adjusted EPS growth from its October preliminary outlook. It anticipates solid underlying growth in 2026, partially offset by select new product headwinds. Management continues to expect a return to 200 basis points above-market organic sales growth in 2027, driven by a diverse portfolio and strong pipeline.

Management Comments

• "Integer delivered strong performance in 2025, achieving 8% sales growth, 13% adjusted operating income growth, and a 21% increase in adjusted EPS."
• "We have tightened the 2026 outlook range around the midpoint of our preliminary outlook provided last October and continue to expect solid underlying growth to be partially offset by select new product headwinds."
• "We remain focused on our strategy of advancing our customers goals through industry-leading engineering and manufacturing."
• "We have built a diverse portfolio and a strong pipeline, positioning Integer to return to 200 basis points above-market organic sales growth in 2027 and deliver sustainable, long-term value for our shareholders."

Industry Context

StockSavvy.ai notes that Integer Holdings, as a leading medical device CDMO, operates in a dynamic healthcare sector. The strong performance in Cardio & Vascular, driven by acquisitions and neurovascular demand, aligns with broader trends of innovation and growth in cardiovascular and neurological device markets. The decline in Neuromodulation from "select emerging customers with PMA products" and the planned exit from Portable Medical suggest strategic portfolio management, focusing on higher-growth or more stable segments. The tightening of the 2026 outlook, while still positive on adjusted EPS, indicates a cautious but confident stance amidst potential new product headwinds, a common challenge in the highly regulated medical device industry.

Comparison to Industry Standards

• Integer's 8% sales growth and 21% adjusted EPS growth in 2025 are strong indicators, potentially outperforming some peers in the medical device CDMO space, which often see growth tied to the overall medical device market (typically 4-6% annually).
• The expectation of 200 basis points above-market organic sales growth in 2027 suggests a strategic advantage or strong product pipeline compared to the average growth rates of the broader medical device industry.
• The leverage ratio of 3.0x adjusted EBITDA is within a manageable range for a company of this size in the industry, especially considering recent acquisitions and share repurchases. Comparable companies like Jabil Healthcare or Flex's Health Solutions segment would typically aim for similar or lower leverage, depending on their growth strategies and M&A activity.

Stakeholder Impact

• Shareholders: Positive impact from strong adjusted EPS growth, share repurchases, and a commitment to long-term value. Potential dilution from convertible notes is mitigated by capped call contracts.
• Employees: Potential impact from restructuring activities (e.g., termination benefits from actions to align labor with manufacturing volumes) mentioned as a non-GAAP adjustment.
• Customers: Continued focus on advancing customer goals through industry-leading engineering and manufacturing, suggesting ongoing partnership and innovation.
• Creditors: Increased total debt and leverage ratio, but within a stated manageable range (3.0x adjusted EBITDA).

Next Steps

• Commence an accelerated share repurchase program (ASR) of approximately $50 million.
• Continue to focus on the strategy of advancing customer goals through industry-leading engineering and manufacturing.
• Return to 200 basis points above-market organic sales growth in 2027.
• Host a conference call on February 19, 2026, at 8 a.m. CT / 9 a.m. ET to discuss these results.

Key Dates

Recommendation

The company delivered strong adjusted financial results for 2025 and has a positive long-term outlook for organic growth. However, the 2026 outlook shows some mixed signals with GAAP metrics declining and adjusted metrics showing modest growth or slight declines at the low end of the range, coupled with increased debt. The share repurchase program is a positive, but the overall picture suggests a "hold" as the market digests the nuanced 2026 guidance and the impact of new product headwinds. Investors should monitor the execution of the 2026 plan and progress towards the 2027 organic growth target.

Keywords

Medical Device, CDMO, Contract Manufacturing, Cardio & Vascular, Neuromodulation, Cardiac Rhythm Management, Financial Results, Earnings, EPS, Sales Growth, Share Repurchase, 2026 Outlook, ITGR, Integer Holdings